Invasive fungal diseases are associated with significant morbidity and mortality, especially in immunocompromised patients. Voriconazole is a first-line treatment for invasive aspergillosis, and an effective agent for candidiasis, fusariosis and scedosporiosis. A growing body of evidence suggests that the efficacy and safety of voriconazole is improved through therapeutic drug monitoring (TDM). Herein, we review key pharmacological features of voriconazole that justify TDM in specific populations, and provide recommendations for how TDM is approached in clinical practice
Lewis, R.E., Viale, P. (2015). Therapeutic drug monitoring of voriconazole. Hauppauge, NY : Nova Science Publishers, Inc..
Therapeutic drug monitoring of voriconazole
LEWIS, RUSSEL EDWARD;VIALE, PIERLUIGI
2015
Abstract
Invasive fungal diseases are associated with significant morbidity and mortality, especially in immunocompromised patients. Voriconazole is a first-line treatment for invasive aspergillosis, and an effective agent for candidiasis, fusariosis and scedosporiosis. A growing body of evidence suggests that the efficacy and safety of voriconazole is improved through therapeutic drug monitoring (TDM). Herein, we review key pharmacological features of voriconazole that justify TDM in specific populations, and provide recommendations for how TDM is approached in clinical practiceI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.